[
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)",
    "summary": "The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies , a safety program to protect patients from risky drugs, for currently approved CAR-T...",
    "url": "https://finnhub.io/api/news?id=e25d1fc808ace2b8b7bfcc086059551d4f790d62acea2084b2b579e57da71ebe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751042231,
      "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)",
      "id": 135656724,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies , a safety program to protect patients from risky drugs, for currently approved CAR-T...",
      "url": "https://finnhub.io/api/news?id=e25d1fc808ace2b8b7bfcc086059551d4f790d62acea2084b2b579e57da71ebe"
    }
  },
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies",
    "summary": "The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies , a safety program to protect patients from risky drugs, for currently approved CAR-T...",
    "url": "https://finnhub.io/api/news?id=c7d67d072552aad2fc71d16b44e87abef8239ec26fdcd765504f46e54aa4f78c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751042231,
      "headline": "US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies",
      "id": 135598956,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies , a safety program to protect patients from risky drugs, for currently approved CAR-T...",
      "url": "https://finnhub.io/api/news?id=c7d67d072552aad2fc71d16b44e87abef8239ec26fdcd765504f46e54aa4f78c"
    }
  },
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapies",
    "summary": "The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation strategies for currently approved Bristol-Myers Squibb's CAR T cell immunotherapies. ...",
    "url": "https://finnhub.io/api/news?id=b029906ff66702be10d8549bc4f422a0d62620fd4252fa637cb46d05a6e0c2a1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751042231,
      "headline": "US FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapies",
      "id": 135597416,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation strategies for currently approved Bristol-Myers Squibb's CAR T cell immunotherapies. ...",
      "url": "https://finnhub.io/api/news?id=b029906ff66702be10d8549bc4f422a0d62620fd4252fa637cb46d05a6e0c2a1"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves label updates for BMS’ CAR T cell therapies",
    "summary": "These updates for Breyanzi and Abecma reduce patient monitoring requirements and removes REMS.",
    "url": "https://finnhub.io/api/news?id=caab31aa63b72e7e94cb7b0b498979aaebbf24cee6512a5f0270f07563cbd557",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751034662,
      "headline": "FDA approves label updates for BMS’ CAR T cell therapies",
      "id": 135591842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "These updates for Breyanzi and Abecma reduce patient monitoring requirements and removes REMS.",
      "url": "https://finnhub.io/api/news?id=caab31aa63b72e7e94cb7b0b498979aaebbf24cee6512a5f0270f07563cbd557"
    }
  },
  {
    "ts": null,
    "headline": "Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies",
    "summary": "The global sickle cell disease treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the demand for effective treatments. North America, led by the U.S., dominates the market with strong healthcare infrastructure, government support, and research innovations. In Asia-Pacific, countries like China and India are experiencing rapid market growth due to rising healthcare expenditure and increased awareness. Europe also contributes significantly, su",
    "url": "https://finnhub.io/api/news?id=2e76e3692da6d08e1ef6925e156aef3543b943f2ab86f7ff300efa08d44c97e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751012520,
      "headline": "Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies",
      "id": 135584785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The global sickle cell disease treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the demand for effective treatments. North America, led by the U.S., dominates the market with strong healthcare infrastructure, government support, and research innovations. In Asia-Pacific, countries like China and India are experiencing rapid market growth due to rising healthcare expenditure and increased awareness. Europe also contributes significantly, su",
      "url": "https://finnhub.io/api/news?id=2e76e3692da6d08e1ef6925e156aef3543b943f2ab86f7ff300efa08d44c97e3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: label update for two therapies",
    "summary": "Bristol Myers Squibb announces that the US FDA has approved updated labeling for its two CAR-T cell therapies, Breyanzi for B-cell lymphoma and other lymphomas, and Abecma for multiple myeloma.This...",
    "url": "https://finnhub.io/api/news?id=28c8f229475653530be495967e7beb72a952ba3f788a0ccddd76ffb545f2c71d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750992852,
      "headline": "Bristol Myers: label update for two therapies",
      "id": 135582407,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces that the US FDA has approved updated labeling for its two CAR-T cell therapies, Breyanzi for B-cell lymphoma and other lymphomas, and Abecma for multiple myeloma.This...",
      "url": "https://finnhub.io/api/news?id=28c8f229475653530be495967e7beb72a952ba3f788a0ccddd76ffb545f2c71d"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
    "summary": "PRINCETON, N.J., June 27, 2025--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
    "url": "https://finnhub.io/api/news?id=32308e89e5f67f3f6614fac0548708f3d93b98948c1e3e5a2156f1edad6d78bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750989900,
      "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
      "id": 135584786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., June 27, 2025--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
      "url": "https://finnhub.io/api/news?id=32308e89e5f67f3f6614fac0548708f3d93b98948c1e3e5a2156f1edad6d78bd"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels",
    "summary": "Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved label updates for both of its CAR T cell therapies, Breyanzi®? for the treatment of large B cell lymphoma and...",
    "url": "https://finnhub.io/api/news?id=07ffd33c14c17048e4962b818a2d31cd08b46b51ed3d7c45bc587d47cb2f41b2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750982721,
      "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels",
      "id": 135578787,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved label updates for both of its CAR T cell therapies, Breyanzi®? for the treatment of large B cell lymphoma and...",
      "url": "https://finnhub.io/api/news?id=07ffd33c14c17048e4962b818a2d31cd08b46b51ed3d7c45bc587d47cb2f41b2"
    }
  }
]